Melanoma Clinical Trials in Cleveland

Showing 121-140 of 152 trials

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

NCT00276536

RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.

Breast CancerKidney CancerLymphoma+4 more

The Cleveland Clinic35 participantsStarted Jan 2001

Cleveland, Ohio, United States

TERMINATEDPHASE1/PHASE2< 1 mile

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550

MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with colon cancer, breast cancer, and melanoma. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies will be taken of a tumor before and once during treatment to measure the effects of the drug. Blood samples will be taken to measure the amount of drug in the blood.

MelanomaColonic NeoplasmsBreast Neoplasms

Pfizer79 participantsStarted Feb 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +14 more locations

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Melanoma Trials in Other Cities

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

CCI-779 in Treating Patients With Metastatic Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Cleveland